SCHEMBL2425189

SCHEMBL2425189

CCN1CCC[C@@H](N)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2425127 1.00
SCHEMBL178341 1.00
Hydrochloric Acid SCHEMBL3975828 0.98 GNAI3 (0.37)
Hydrochloric Acid SCHEMBL2425478 0.98 GNAI3 (0.37)
Hydrochloric Acid SCHEMBL27095266 0.98 GNAI3 (0.37)
Hydrochloric Acid SCHEMBL25417087 0.98 GNAI3 (0.37)
Hydrochloric Acid SCHEMBL2427708 0.98 GNAI3 (0.37)
SCHEMBL4703206 0.93 CHRM5 (0.37)
SCHEMBL7804683 0.93 CHRM5 (0.37)
SCHEMBL7810418 0.93 CHRM5 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2576537-B1 2-AMINO-PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK HOFFMANN LA ROCHE (CH) 2016-03-16 EP claimed
US-8642601-B2 Inhibitors of JNK ROCHE PALO ALTO LLC (US) 2014-02-04 US claimed
US-20110301171-A1 Inhibitors of JNK ARZENO HUMBERTO BARTOLOME (US) 2011-12-08 US claimed
EP-4347571-B1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. HOFFMANN LA ROCHE (CH) 2026-04-22 EP disclosed
CN-121586712-A Novel compounds 豪夫迈·罗氏有限公司 2026-02-27 CN disclosed
EP-4683918-A1 NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-01-28 EP disclosed
EP-4655287-A2 INHIBITORS OF NLRP3 MWYNGIL THERAPEUTICS, INC. (US) 2025-12-03 EP disclosed
US-20250353830-A1 NOVEL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-11-20 US disclosed
EP-4642772-A1 NLRP3 INFLAMMASOME INHIBITORS Astrazeneca AB (SE) 2025-11-05 EP disclosed
EP-4637746-A1 6,6 BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 Merck Sharp & Dohme LLC (US) 2025-10-29 EP disclosed
EP-4630420-A1 INHIBITORS OF NLRP3 F. Hoffmann-La Roche AG (CH) 2025-10-15 EP disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-02-19 US disclosed
US-7297695-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-20 US disclosed